top of page
Якорь 5
AdobeStock_201606402_edited.jpg
Autism Global Challenge Ecosystem

Autism Spectrum Disorder (ASD) is widely prevalent worldwide, posing challenges for effective treatment in clinics and leading to extensive health consequences. Autism is a group of psychological developmental disorders characterized by a combination of social interaction impairments, communication difficulties, and stereotypical behavior. At Deep Knowledge Group and Longevity Industry Analytics, we recognize the severity of this crisis and possess the profound expertise necessary to mitigate its consequences. 

 

Our primary goal is to halt the spread of this widespread condition and minimize or, ideally, eliminate its long-term health implications. Thanks to our experience and analytics in this field, coupled with modern clinics, we have unique capabilities to alleviate the burden of ASD. We actively invite investors and partners to collaborate with us in an advanced approach to addressing this urgent global issue. Together, we can influence the course of events and contribute to more effective management of this challenge in modern medicine.

Global Perspective

Autism Spectrum Disorder (ASD) stands as one of the most commonly diagnosed neurodevelopmental conditions globally. More than 75 million people have been diagnosed with this condition. Understanding factors influencing ASD prevalence is crucial for effective prevention, diagnosis, and management.

The spectrum nature of ASD manifests in diverse ways, encompassing a wide range of strengths and challenges in communication, social interaction, and behavior. Delving deeper into the landscape of ASD, ongoing research continues to unveil the intricate factors influencing its prevalence. Genetic, environmental, and neurological elements contribute to the diverse spectrum of ASD presentations. By staying at the forefront of advancements in understanding these factors, our specialists aim to refine and personalize treatment approaches for individuals on the autism spectrum.

Percent of people with ASD

Autism Global Ecosystem

Autism & Lyme Disease:

Exploring Connections

Recent investigations have delved into a potential association between Lyme disease and certain forms of autism. The observed association between Lyme disease and an elevated likelihood of autism or developmental disorders, particularly in children, underscores the importance of continued exploration in this realm. Furthermore, the higher prevalence of Lyme disease antibodies in individuals with autism, as highlighted in the studies, adds another layer of complexity to this intricate relationship.

The proposed theories, namely the role of Lyme disease-induced brain inflammation and the potential impact of borrelia bacteria on neurotransmitter levels, provide valuable avenues for understanding the mechanisms at play. These theories offer potential insights into the development of autism or related neurological disorders. However, it is imperative to recognize that these findings are preliminary, and further in-depth research is essential to validate and refine our understanding of the nuanced connections between Lyme disease and Autism.

Снимок экрана 2024-01-27 в 14.25.33.png

The proposed theories, namely the role of Lyme disease-induced brain inflammation and the potential impact of borrelia bacteria on neurotransmitter levels, provide valuable avenues for understanding the mechanisms at play. These theories offer potential insights into the development of autism or related neurological disorders. However, it is imperative to recognize that these findings are preliminary, and further in-depth research is essential to validate and refine our understanding of the nuanced connections between Lyme disease and Autism.

Autism Global Ecosystem GeoDashboard

1600+

Clinic Trials 

300+

Top Clinics

200+

Investors 

20000+ 

Data Points 

Якорь 3

Autism Market in Charts

Anticipated to undergo significant expansion, the global market for Autism Spectrum Disorder (ASD) treatment is poised to grow from USD 29.8 billion in 2021 to USD 45.9 billion in 2032, reflecting a robust Compound Annual Growth Rate (CAGR) of around 4.4%.

The upsurge in healthcare advancements, backed by substantial investments from major corporations and government institutions, underscores the increasing importance of precise diagnostics and refined treatment approaches in addressing the intricacies of Autism Spectrum Disorder (ASD). This extends to providing comprehensive support for individuals across the entire spectrum, including those with mild forms.

Lyme Disease Diagnostics Market Size, $bn

Experiencing a Compound Annual Growth Rate (CAGR) of approximately 8% during this period, the market for Autism Spectrum Disorder (ASD) diagnostic tools is on a robust trajectory. This growth is propelled by heightened awareness and reporting of ASD cases, advancements in diagnostic technologies, and sustained investments in research and development aimed at creating more precise and effective diagnostic tools.

 

Projections indicate a steady market expansion, with an anticipated rise from USD 2 billion in 2022 to USD 5.4 billion in 2032. This underscores the increasing demand for advanced diagnostic solutions in detecting Autism Spectrum Disorder, with a focus on early identification and enhanced condition management.

Solutions for Global Health Challenges 

The Lyme Pandemia with Diabetes, Autism and Alzheimer Diseases pose a significant challenge, with a growing pharmaceutical market each year. Despite this expansion, the issue persists, highlighting the complexity and difficulty in finding a comprehensive resolution to the problem. This group of diseases are not effectively addressed solely through standard treatments.

 

At DKG, we frequently encounter people facing challenges in managing their symptoms even after undergoing conventional therapy. Drawing on over a decade of analytical expertise, we have accumulated and explored advanced holistic methods to effectively impact on the spread of these problems in the World. 

Our proficiency in treating such diseases revolves around discerning the coinfections and other complicating factors associated with these  ailment. To tackle this distinct set of considerations our specialists employ personalized proprietary treatments that integrate cutting-edge and natural therapies related to Mitochondrial, Space, Restorative, Functional Medicine within the framework of Longevity Medicine.

Снимок экрана 2024-02-08 в 20.58.07.png
Снимок экрана 2024-02-08 в 20.59.02.png
Снимок экрана 2024-02-08 в 21.00.31.png
Снимок экрана 2024-02-08 в 21.01.44.png

Global Autism Dashboard

The Global Autism Dashboard is a centralized hub designed to meet all the market and business intelligence needs of its users. It offers comprehensive support, encompassing benchmarking for companies, technologies, and thorough competitive and SWOT analysis for over 1646 clinical trials, 300+ clinical trials, 200+ investors, and 20,000+ data inputs within the ASD sector.

Снимок экрана 2023-12-09 в 14.27.38.png
Screenshot Autism.png

Autism Patient Logistic Journey Map

Explore the comprehensive journey of ASD patients through the interactive logistic pathway. Each stage offers a concise overview, and by selecting individual stages, you can delve into detailed descriptions that provide insights into AI-driven diagnostic, treatment, and management processes tailored specifically to ASD. For more in-depth information about clinics, diagnostics, and treatments, use the Global Autism Dashboard.

Teaser

Autism Teaser new.png

One Pager

Autism One-pager new.png

Report

Autism Report new.png
Якорь 4

Autism Clinical Trials

The United States stands as the primary research center for ASD clinical trials, hosting over 53% of these studies.

 

More than 5% of clinical trials are launched in France. Canada, Taiwan, UK and China have similar number of clinical trials, each around 3%. Together, European countries make more than 18% of clinical trials. In total, more than 50 countries have participated in Autism Spectrum Disorder clinical trials.

After 2017, the annual number of clinical trials more than doubled increasing to 134 studies per year. The jump in clinical trials after 2017 signals a rising awareness of ASD significance.

The most significant players in the market are Massachusetts General Hospital (USA), Stanford University (USA), National Taiwan University Hospital (Taiwan), Yale University (USA), University of California, Los Angeles (USA),  Children's Hospital Medical Center, Cincinnati (USA), National Institute of Mental Health (USA).

Strategic Partner Projects

lyme.png

Lyme Disease

Global Pandemia

alzheimers_edited_edited_edited.jpg

Alzheimer's Global

Challenge Ecosystem